share_log

Decoding 6 Analyst Evaluations For Pacira BioSciences

Benzinga ·  07:00

Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:PCRX), expressing a variety of opinions spanning from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings30300
Last 30D10000
1M Ago10200
2M Ago00000
3M Ago10100

The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.17, a high estimate of $39.00, and a low estimate of $15.00. Highlighting a 2.31% decrease, the current average has fallen from the previous average price target of $21.67.

bigjpg

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of Pacira BioSciences...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment